(PDF) Methodological Analyses of Budget Impact Models

Methodological Analyses of Budget Impact Models Submitted to the Haute Autorité De Santé (HAS) (French National Authority for Health)

Value in Health - United Kingdom

doi 10.1016/j.jval.2017.08.2094

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2017

Authors

Publisher

Elsevier BV

Related search

Pmu15 - Analysis of the Methodological Objections Regarding Indirect Treatment Comparison Submitted to the Haute Autorité De Santé (Has)

English

Use of Budget Impact Analysis (Bia) in Economic Evaluations of Drugs and Medical Devices Submitted to the French National Authority for Health (Has)

English

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

English

Exploring Uncertainty in Economic Evaluation of Medicines: A Review of the First Manufacturers' Submissions to the French National Authority for Health (Has)

English

A Methodological Review of US Budget-Impact Models for New Drugs

English

Pmu25 - Examining the Consistency and Accuracy of the Budget Impact Models Submitted to the National Centre for Pharmacoeconomics in Ireland to Aid the Creation of an Applicant Template

English

Php213 - A Retrospective Review of Reimbursement Decisions by the Haute Autorité De Santé in 2017 - Underlying Rationale for Medicinal Products With Insufficient Actual Medical Benefit

English

Ht7 - A Review of Efficiency Opinions of French ‘Haute Autorite De Sante’ (Has) in the Oncology Field

English

Php322 - Real-World Data : What Are the Use and Requirements in Health-Economic Appraisals in Reinscription by the French Haute Autorite De Sante (Has)?

English

Amanote Research

Methodological Analyses of Budget Impact Models Submitted to the Haute Autorité De Santé (HAS) (French National Authority for Health)

Value in Health - United Kingdom

doi 10.1016/j.jval.2017.08.2094

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Pmu15 - Analysis of the Methodological Objections Regarding Indirect Treatment Comparison Submitted to the Haute Autorité De Santé (Has)

Use of Budget Impact Analysis (Bia) in Economic Evaluations of Drugs and Medical Devices Submitted to the French National Authority for Health (Has)

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

Exploring Uncertainty in Economic Evaluation of Medicines: A Review of the First Manufacturers' Submissions to the French National Authority for Health (Has)

A Methodological Review of US Budget-Impact Models for New Drugs

Pmu25 - Examining the Consistency and Accuracy of the Budget Impact Models Submitted to the National Centre for Pharmacoeconomics in Ireland to Aid the Creation of an Applicant Template

Php213 - A Retrospective Review of Reimbursement Decisions by the Haute Autorité De Santé in 2017 - Underlying Rationale for Medicinal Products With Insufficient Actual Medical Benefit

Ht7 - A Review of Efficiency Opinions of French ‘Haute Autorite De Sante’ (Has) in the Oncology Field

Php322 - Real-World Data : What Are the Use and Requirements in Health-Economic Appraisals in Reinscription by the French Haute Autorite De Sante (Has)?